Tharimmune presents favorable th104 phase 1 clinical data at the american college of gastroenterology 2024 annual scientific meeting

Th104, the company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile th104 was well tolerated with no unexpected treatment-emergent adverse events, supporting further clinical development company expects phase 2 topline data for chronic pruritus in primary biliary cholangitis (pbc) patients in 2025 bridgewater, nj / accesswire / october 28, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new th104 phase 1 data at the american college of gastroenterology (acg) 2024 annual scientific meeting, underway in philadelphia. the phase 1 trial was a single-dose, single-center, open-label, randomized study of th104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease (cld).
THAR Ratings Summary
THAR Quant Ranking